Quinn, an ~18 month old boy with autism, obsessively stacking cans. Credit: Copyright (c) 2003 by Nancy J Price (aka Mom).

Zynerba Pharmaceuticals has initiated a Phase II clinical trial of its cannabinoid (CBD) gel Zygel (ZYN002) for the treatment of children and adolescents with autism spectrum disorder (ASD).

Zygel is a pharmaceutically-manufactured CBD available as a permeation-enhanced clear gel formulation. It is intended for controlled, transdermal drug delivery into the bloodstream.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Prior studies indicate that autism could be related to a disruption in the endocannabinoid (EC) system. Other research suggests CBD may modify the EC system and improve some core social and behavioural symptoms associated with autism.

The open-label, multi-dose Phase II BRIGHT trial will investigate the safety, tolerability and efficacy of Zygel in around 36 ASD patients aged four to 17.

“Though there has been an accelerating rate of diagnosis, to date there are only two FDA approved products indicated for the treatment of ASD symptoms.”

Participants will be administered with weight-based initial daily doses of 250mg or 500mg.

The efficacy assessments will be conducted using the Aberrant Behavior Checklist, Parent Rated Anxiety Scale – Autism Spectrum Disorder, Autism Impact Measure and Clinical Global Impression – Severity and Improvement.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Top-line results from the BRIGHT trial are expected to be available in the first half of next year.

Zynerba Pharmaceuticals chairman and CEO Armando Anido said: “Though there has been an accelerating rate of diagnosis, to date there are only two FDA approved products indicated for the treatment of ASD symptoms. Both have significant side effect profiles, and neither have been approved to address the key symptoms of social impairment and anxiety.

“We are excited to initiate the BRIGHT trial evaluating the role of Zygel in ASD and are hopeful that Zygel may improve some of the core social and behavioural symptoms of ASD.”

The company started a pivotal trial of ZYN002 in patients with Fragile X syndrome (FXS) in July last year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact